Contrasting Intellia Therapeutics (NASDAQ:NTLA) and BeyondSpring (NASDAQ:BYSI)

BeyondSpring (NASDAQ:BYSI) and Intellia Therapeutics (NASDAQ:NTLA) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, earnings, profitability and institutional ownership.

Volatility & Risk

BeyondSpring has a beta of -0.21, indicating that its stock price is 121% less volatile than the S&P 500. Comparatively, Intellia Therapeutics has a beta of 1.8, indicating that its stock price is 80% more volatile than the S&P 500.

Valuation & Earnings

This table compares BeyondSpring and Intellia Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeyondSpring	$1.75 million	13.14	-$1.01 million	($0.12)	-4.66
Intellia Therapeutics	$67.67 million	23.65	-$412.69 million	($3.36)	-3.40

BeyondSpring has higher earnings, but lower revenue than Intellia Therapeutics. BeyondSpring is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings for BeyondSpring and Intellia Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeyondSpring	1	0	0	0	1.00
Intellia Therapeutics	5	8	9	1	2.26

Intellia Therapeutics has a consensus target price of $20.72, suggesting a potential upside of 81.41%. Given Intellia Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Intellia Therapeutics is more favorable than BeyondSpring.

Profitability

This table compares BeyondSpring and Intellia Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BeyondSpring	N/A	N/A	-28.88%
Intellia Therapeutics	-672.16%	-57.79%	-47.29%

Institutional & Insider Ownership

40.3% of BeyondSpring shares are owned by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are owned by institutional investors. 29.3% of BeyondSpring shares are owned by insiders. Comparatively, 3.5% of Intellia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Intellia Therapeutics beats BeyondSpring on 8 of the 14 factors compared between the two stocks.

About BeyondSpring

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

About Intellia Therapeutics

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.